

X-markets Programme

Issue of up to 50,000 (Deutsche Bank AG (DE) New Pharma Equities Note (90) 2030 (corresponds to product no. N64 in the Securities Note) relating to MSCI World IMI New Pharma Select 5% Decrement Index (the "Securities")

WKN: DC5PR1 ISIN: XS2011161044

Notice to Securityholders

This Notice is dated 28 June 2021 and should be read in conjunction with the Final Terms dated 17 May 2021 in respect of the Issue of up to 50,000 (Deutsche Bank AG (DE) New Pharma Equities Note (90) 2030 (corresponds to product no. N64 in the Securities Note) relating to MSCI World IMI New Pharma Select 5% Decrement Index (the "Securities"), to be issued by Deutsche Bank AG Frankfurt am Main.

Any information not updated or amended herein should be regarded as unchanged.

Further to its public offer of the Issue of up to 50,000 (Deutsche Bank AG (DE) New Pharma Equities Note (90) 2030 (corresponds to product no. N64 in the Securities Note) relating to MSCI World IMI New Pharma Select 5% Decrement Index (the "Securities"), to be issued by Deutsche Bank AG Frankfurt (the "Issuer") under its X-markets Programme (each a "Security" together the "Securities"), the Issuer will issue EUR 6,534,000 at an Issue Price of 102.00% of the Nominal Amount (Nominal Amount being EUR 1,000 per Security).

The Issue Date of the Notes is 30 June 2021.

Application has been made to list the Securities on the Official List of the Luxembourg Stock Exchange and to trade them on the Regulated market of the Luxembourg Stock Exchange, which is a regulated market for the purposes of Directive 2014/65/EU (as amended).

28 June 2021

Deutsche Bank